Stephen Machatha - 30 Mar 2022 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role: Chief Development Officer
Signature: /s/ Stephen Machatha
Issuer symbol: ALDX
Transactions as of: 30 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Apr 2022, 19:37:08 UTC
Next filing: 19 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALDX	Common Stock	Award	$0	+64,395	+277%	$0.000000	87,658	30 Mar 2022	Direct	F1, F2
holding	ALDX	Common Stock						211	30 Mar 2022	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALDX	Employee Stock Option (Right to Buy)	Award	$0	+250,000		$0.000000	250,000	30 Mar 2022	Common Stock	250,000	$4.52	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
F2	Includes 2,972 shares previously purchased under the Issuer's Employee Stock Purchase Plan.
F3	These shares are held directly by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over these shares for purposes of Section 16 or for any other purposes.
F4	The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.